PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Liraglutide - Weight management in adults

PAD Profile : Liraglutide - Weight management in adults

Keywords :
obesity, overweight, weight loss
Brand Names Include :
Saxenda

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

A Medicines Shortage Notification has been issued in relation to the supply shortages of GLP-1s.

See GLP-1 Medicine Shortage document below for full details

03 November 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) have approved:

  • the updated guidance for the Management of Obesity in Adults
  • Liraglutide (Saxenda) referral criteria and pathway

See documents below

03 March 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC recommends the use of liraglutide (prescribed as Saxenda) as an option for managing overweight and obese patients in line with NICE TA664 (see link to NICE below).

Liraglutide (Saxenda) will be considered RED on the traffic light system.

Weight management local guidance will be updated and referreal criteria to be developed with ASPH

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More